Overview

Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial

Status:
Completed

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

This is a randomized phase II, open label, two arm study, evaluating the efficacy of panitumumab in combination with Trifluridine-Tipiracilas third line therapy, after a first line containing an anti-EGFR agent panitumumab(at least 70% of study population) or cetuximab.

Phase:

Phase 2

Details

Lead Sponsor:

University of Campania "Luigi Vanvitelli"

Treatments:

Panitumumab
Trifluridine